VBI Vaccines Non-GAAP EPS of -$0.09 misses by $0.02, revenue of $0.35M misses by $0.35M

Aug. 08, 2022 8:32 AM ETVBI Vaccines Inc. (VBIV)By: Pranav Ghumatkar, SA News Editor3 Comments
  • VBI Vaccines press release (NASDAQ:VBIV): Q2 Non-GAAP EPS of -$0.09 misses by $0.02.
  • Revenue of $0.35M (+150.0% Y/Y) misses by $0.35M.
  • Two new clinical studies in GBM patients expected to start before the end of 2022
  • In partnership with the Government of Canada, new clinical study assessing pan-coronavirus vaccine candidate expected to start in Q3 2022
  • Initial Phase 2 human proof of concept combination study data from VBI-2601 + siRNA in chronically infected HBV patients expected by year-end 2022
  • VBI ended the second quarter of 2022 with $82.4 million in cash compared with $121.7 million in cash as of December 31, 2021.
  • Shares -11.21% PM.

Recommended For You

Comments (3)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.